Neutralizing antibodies to HIV-1 and their use

US10035845B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10035845-B2
Application numberUS-201715661867-A
CountryUS
Kind codeB2
Filing dateJul 27, 2017
Priority dateSep 25, 2009
Publication dateJul 31, 2018
Grant dateJul 31, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and the use of these antibodies are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using epitope scaffold probes.

First claim

Opening claim text (preview).

We claim: 1. An isolated nucleic acid molecule, comprising: a nucleotide sequence encoding: an antibody heavy chain variable region comprising a heavy chain complementarity determining region (HCDR) 1, a HCDR2, and a HCDR3, comprising amino acids 26-33, 51-58, and 97-110, of SEQ ID NO: 1, respectively; an antibody light chain variable region comprising a light chain complementarity determining region (LCDR) 1, a LCDR2, and a LCDR3, comprising amino acids 27-30, 48-50, and 87-91, of SEQ ID NO: 2, respectively; or an antibody comprising a heavy chain variable region comprising a HCDR1, a HCDR2, and a HCDR3, comprising amino acids 26-33, 51-58, and 97-110, of SEQ ID NO: 1, respectively, and an antibody light chain variable region comprising a LCDR1, a LCDR2, and a LCDR3, comprising amino acids 27-30, 48-50, and 87-91, of SEQ ID NO: 2, respectively, wherein the antibody specifically binds to gp120. 2. The isolated nucleic acid molecule of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 1. 3. The isolated nucleic acid molecule of claim 1 , wherein the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 2. 4. The isolated nucleic acid molecule of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 3. 5. The isolated nucleic acid molecule of claim 1 , wherein the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 4. 6. The isolated nucleic acid molecule of claim 1 , wherein the heavy chain variable region comprises the HCDR1, the HCDR2, and the HCDR3, and an amino acid sequence at least 90% identical to the amino acid sequence set forth as SEQ ID NO: 1. 7. The isolated nucleic acid molecule of claim 1 , wherein the light chain variable region comprises the LCDR1, the LCDR2, and the LCDR3, and an amino acid sequence at least 90% identical to the amino acid sequence set forth as SEQ ID NO: 2. 8. The isolated nucleic acid molecule of claim 1 , comprising: the nucleotide sequence encoding the antibody comprising the heavy chain variable region comprising a HCDR1, a HCDR2, and a HCDR3, comprising amino acids 26-33, 51-58, and 97-110, of SEQ ID NO: 1, respectively, and the antibody light chain variable region comprising a LCDR1, a LCDR2, and a LCDR3, comprising amino acids 27-30, 48-50, and 87-91, of SEQ ID NO: 2, respectively; and wherein the antibody specifically binds to gp120. 9. The isolated nucleic acid molecule of claim 1 , wherein the heavy chain variable region comprises the HCDR1, the HCDR2, and the HCDR3, and an amino acid sequence at least 90% identical to the amino acid sequence set forth as SEQ ID NO: 1; and the light chain variable region comprises the LCDR1, the LCDR2, and the LCDR3, and an amino acid sequence at least 90% identical to the amino acid sequence set forth as SEQ ID NO: 2. 10. The isolated nucleic acid molecule of claim 1 , wherein the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 1, and the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 2. 11. The isolated nucleic acid molecule of claim 10 , wherein the antibody is an IgG, an IgM, or an IgA. 12. The isolated nucleic acid molecule of claim 11 , wherein the antibody is an IgG 1. 13. An isolated nucleic acid molecule, comprising a nucleotide sequence encoding an antigen binding fragment of the antibody encoded by the nucleic acid molecule of claim 8 . 14. The isolated nucleic acid molecule of claim 13 , wherein the antigen binding fragment is a Fab fragment, a Fab′ fragment, a F(ab)′ 2 fragment, a single chain Fv protein (scFv), or a disulfide stabilized Fv protein (dsFv). 15. The isolated nucleic acid molecule of claim 1 , wherein the nucleic acid sequence comprises at least one of one of the nucleic acid sequences set forth as SEQ ID NOs: 29-32. 16. The isolated nucleic acid molecule of claim 1 , operably linked to a promoter. 17. An expression vector comprising the isolated nucleic acid molecule of claim 1 . 18. The expression vector of claim 17 , wherein the expression vector is a viral vector. 19. The expression vector of claim 18 , wherein the viral vector is an adeno-associated viral vector. 20. An isolated host cell transformed with the nucleic acid molecule of claim 1 . 21. A method of making an antibody that specifically binds to gp120, comprising: expressing in a host cell one or more nucleic acid molecules encoding: an antibody heavy chain variable region comprising a heavy chain complementarity determining region (HCDR) 1, a HCDR2, and a HCDR3, comprising amino acids 26-33, 51-58, and 97-110, of SEQ ID NO: 1, respectively; and an antibody light chain variable region comprising a light chain complementarity determining region (LCDR) 1, a LCDR2, and a LCDR3, comprising amino acids 27-30, 48-50, and 87-91, of SEQ ID NO: 2, respectively; and purifying the antibody.

Assignees

Inventors

Classifications

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10035845B2 cover?
Monoclonal neutralizing antibodies are disclosed that specifically bind to the CD4 binding site of HIV-1 gp120. Monoclonal neutralizing antibodies also are disclosed that specifically bind to HIV-1 gp41. The identification of these antibodies, and the use of these antibodies are also disclosed. Methods are also provided for enhancing the binding and neutralizing activity of any antibody using e…
Who is the assignee on this patent?
Us Health, Univ Washington
What technology area does this patent fall under?
Primary CPC classification C07K16/1145. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jul 31 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).